Issue 5, 2021

Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research

Abstract

Covering: up to 2020

This short review surveys aspects of glycolipid-based natural products and their biological relevance in multiple sclerosis (MS). The role of isolated gangliosides in disease models is discussed together with an overview of ganglioside-inspired small molecule drugs and imaging probes. The discussion is extended to neurodegeneration in a more general context and addresses the need for more efficient synthetic methods to generate (glyco)structures that are of therapeutic relevance.

Graphical abstract: Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research

Article information

Article type
Review Article
Submitted
03 Dec 2020
First published
12 Feb 2021

Nat. Prod. Rep., 2021,38, 890-904

Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research

L. Nowack, C. S. Teschers, S. Albrecht and R. Gilmour, Nat. Prod. Rep., 2021, 38, 890 DOI: 10.1039/D0NP00093K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements